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MEDICAID DRUG SPENDING AFTER THE MEDICARE
MODERNIZATION ACT: WHAT WILL BE LEFT?
Boulanger L, Brown J, Menzin J
Boston Health Economics, Inc, Waltham, MA, USA
OBJECTIVES: To evaluate drug expenditures among Medicaid
recipients who are not also Medicare eligible and therefore
whose costs will still be paid by Medicaid following implemen-
tation of the Medicare Modernization Act (MMA). METHODS:
We analyzed 2002 pharmacy claims data and eligibility records
from a 20% random sample of California Medicaid (“Medi-
Cal”) recipients. The number of unique patients, prescriptions
dispensed, units dispensed, and Medicaid paid amounts were
obtained for each class of pharmaceuticals. Patients were con-
sidered dually eligible if they were eligible for Medicare and
Medicaid coverage for at least one month in 2002. Medicaid
payments, excluding rebates, were projected to the entire Medi-
Cal program. For simplicity, we report ﬁndings from the top ten
drug classes in terms of total Medicaid projected payments and
the percentage paid for non-dually eligible recipients. RESULTS:
We estimated that California Medicaid spent approximately
$1.98 billion for the top ten classes of drugs. These classes rep-
resented approximately 53% of total Medi-Cal drug expendi-
tures in 2002. Forty-three percent of these payments were for
recipients who were not dually eligible for Medicare and Med-
icaid. The top ten classes in terms of expenditures were (with
amount paid and percent paid for non-dually eligible recipients
in parentheses): antipsychotics ($530 million, 55%), gastro-
intestinal drugs ($228 million, 32%), antidepressants ($220
million, 50%), antivirals ($191 million, 49%), antihyperlipi-
demics ($172 million, 27%), NSAIDs ($162 million, 33%), anti-
convulsants ($142 million, 53%), antidiabetics ($122 million,
32%), calcium channel blockers ($113 million, 24%), and opiate
agonists ($96 million, 43%). CONCLUSION: The California
Medicaid program will remain responsible for a substantial
portion of drug spending for central nervous system disorders
following implementation of the MMA, but the cost burden for
cardiovascular medications will be lowered greatly.
HP2
EFFECTS OF PATIENTS’ BELIEFS ABOUT MEDICATIONS ON
NON-ADHERENCE TO CHRONIC MEDICATIONS
Phatak HM,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Non-adherence to medications is a major
problem among patients using chronic medications. Patients’
medication beliefs are among modiﬁable factors considered to
inﬂuence non-adherence. The primary aim of this study was to
investigate associations between patients’ beliefs about medica-
tions and non-adherence to chronic medications. METHODS: A
cross-sectional self-administered survey was conducted of
patients visiting a primary care clinic. Participants’ medication
beliefs and medication non-adherence were assessed using the
Beliefs about Medications Questionnaire as developed by Horne
et al. and the Morisky Medication Adherence Scale. Sociode-
mographic and clinical information also were collected. 
Spearman correlation analyses were used to assess associations
between medication beliefs and medication non-adherence.
RESULTS: A total of 443 patients were approached and 314 met
study criteria of using at least one chronic medication for more
than 2 months and ability to speak English. Of the 314 patients
meeting inclusion criteria, 250 agreed to complete the survey, a
response rate of 79.6%. Most of the participants (62.25%) were
between 30 and 49 years old. Whites constituted 53% and blacks
constituted 40% of the sample. Participants had a mean of 3.2
conditions (±2.1) and used a mean of 5.3 medications (±4.1).
Participants perceiving less necessity to use medications (r =
-0.2, p = 0.005) and with higher concerns about medications 
(r = 0.4, p < 0.0001) had higher non-adherence to medications.
Participants perceiving higher general harmful effects of med-
ications (r = 0.3, p < 0.0001) and with higher perceptions of
over-prescribing of medications by physicians (r = 0.3, p <
0.0001) had higher non-adherence to medications. Medication
beliefs predicted 22% of variation in non-adherence to chronic
medications. CONCLUSION: There were signiﬁcant associa-
tions between medication beliefs and non-adherence. Health care
providers may help patients improve their adherence to medica-
tions by resolving issues identiﬁed through medication beliefs
assessment.
HP3
WHO WILL REQUEST A SWITCH TO NEW TREATMENT AS A
RESULT OF DIRECT-TO-CONSUMER ADVERTISING?
Chen HD, Carroll N
Virginia Commonwealth University, Richmond,VA, USA
OBJECTIVES: To identify the factors that inﬂuence consumers
to request a switch to new treatment as a result of Direct-
to-Consumer (DTC) advertising. METHODS: Data were taken
from a national survey, “Public Health Impact of Direct-to-
Consumer Advertising of Prescription Drugs, July 2001–January
2002”, conducted by researchers from Harvard Medical School.
Participants (n = 3000) were interviewed by telephone. We con-
structed a conceptual framework consisting of outcome (switch-
ing request), intervention (DTC experience) and ﬁve groups of
explanatory factors (health beliefs, demographics, health status,
socioeconomic status and market factors). Data were analyzed
with multivariate stepwise logistic regression. The dependent
variable was whether a DTC advertisement for a prescription
drug had ever prompted the patient to ask for a change to 
new treatment for a medical condition or illness. RESULTS:
Health beliefs were strong predictors of switching request.
Patients who regarded media as the most important referent
source were more likely to make requests than those who did
not. (OR, 4.8; 95%CI, 3.42–6.71). Believing that DTC adver-
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